10x Genomics enters the final week of June with a Barclays target raise landing just as options positioning hits its most bullish extreme of the past year — a confluence that sharpens the tension between a still-heavy short base and a rapidly improving sentiment backdrop.
The most striking data point this week came from the Street. Barclays analyst Luke Sergott raised his price target on TXG to $40 from $30, maintaining Overweight — a 33% lift that takes his target well above both the current price of $31.87 and the consensus mean near $27.60. That gap between Barclays and the broader Street is meaningful: JPMorgan and Morgan Stanley, both of which raised targets in May, remain at $20 and $22 respectively with neutral-equivalent ratings, framing a clear bull-bear divide among major firms. Bulls cite consumables volume recovery and a potential 5-19x per-platform expansion by 2027; bears point to the 2024 revenue contraction, persistent pricing headwinds, and a valuation that offers little margin for error — the price-to-book multiple has expanded roughly 47% over the past 30 days alongside the stock's rally, and the EV/EBITDA remains deeply negative.
Options positioning has tilted dramatically in the bullish direction, and the magnitude is worth flagging. The put/call ratio collapsed to 0.16 on Tuesday — more than 2.4 standard deviations below its 20-day average of 0.30, and near the 52-week floor of 0.06. That reading represents the heaviest net call demand relative to recent norms that TXG options have seen all year. The shift is abrupt: the PCR ran near 0.31 as recently as last week, suggesting the Barclays upgrade may have accelerated call buying rather than simply coinciding with pre-existing positioning.
Short interest tells a steadier story after the fireworks of the prior week. The previous note documented a sharp drop from ~20.5 million shares to ~14.4 million in early June; since then, short interest has been largely flat, nudging to 17.25 million shares — essentially unchanged on the week, down just 9% from last week's reading. At 14.8% of the free float, bears retain a structurally significant position. The borrow market gives them no urgency to cover: cost to borrow is just 0.41%, down slightly on the month, and availability is extraordinarily loose at 646% — meaning roughly six-and-a-half shares are available to borrow for every one already lent out. Shorts who remain are not being squeezed; they are choosing to stay.
Institutional ownership adds an interesting layer to the picture. FMR (Fidelity) added roughly 5.8 million shares in the most recent reporting period, making it the largest holder at nearly 15% of the company. ARK Investment Management holds another 9.2%, with minimal recent change. Goldman Sachs added 1.46 million shares in Q1, a notable position build from a firm that does not typically feature prominently in single-cell genomics names. Co-founders Serge Saxonov and Ben Hindson — the CEO and CSO respectively — have been consistent sellers throughout the period, with Saxonov logging sales across March, April, and May. The 90-day net insider figure of roughly 81,000 shares held is essentially flat, reflecting small offsetting grant-related activity, but the directional pattern from the executive team is one of steady, methodical reduction as the stock has recovered.
Earnings history adds a cautionary note. The last two prints produced immediate-day declines of 3.5% and 5.0%, with five-day moves of -9.7% and -5.4% respectively. The next report is pencilled in for August 7 — six weeks away. The ORTEX short score has eased slightly this week to 60.0, down from a brief spike to 64.3 on June 15, suggesting the aggregate bearish signal has moderated but remains elevated relative to peers. With the Barclays target now the highest on the Street, August 7 will test whether the consumables recovery thesis has enough substance to justify pricing that has already run 35% higher this month.
See the live data behind this article on ORTEX.
Open TXG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
